Search results for "epiderma"

showing 10 items of 296 documents

Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome

2008

Abstract Introduction: Magnesium plays a role in a large number of cellular metabolic reactions. Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) transport in the kidney. We designed this trial to investigate if Mg2+ serum level modifications may be related with clinical response and outcome in advanced colorectal cancer patients during treatment with cetuximab plus irinotecan. Experimental Design: Sixty-eight heavily pretreated metastatic colorectal cancer patients were evaluated for Mg2+ serum levels at the following time points: before; 6 hours; and 1, 7, 14, 21, 50, and 92 days after the start of treatment. Results: Basal Mg2+ median levels were significan…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerCetuximabmagnesiumcolorectal cancerAntibodies Monoclonal HumanizedIrinotecanGastroenterologyHypomagnesemiaBasal (phylogenetics)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMagnesiumEpidermal growth factor receptorNeoplasm MetastasisAgedAged 80 and overCetuximabbiologybusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseIrinotecanGene Expression Regulation NeoplasticEndocrinologyTreatment OutcomeOncologyMonoclonalbiology.proteinDisease ProgressionCamptothecinFemalebusinessColorectal Neoplasmsmedicine.drug
researchProduct

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epider…

2011

Purpose We conducted a phase I dose-escalation study to characterize the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic properties of RG7160 (GA201), a humanized and glycoengineered immunoglobulin G1 anti–epidermal growth factor receptor (EGFR) monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity. Patients and Methods Seventy-five patients with advanced EGFR-positive solid tumors received RG7160 (50 to 1,400 mg) administered every week, every 2 weeks, or every 3 weeks. Dose escalation followed a three-plus-three trial design. Results No maximum-tolerated dose was reached for any dosing schedule. Common adverse events (AEs) included rash (80% of patien…

AdultMaleCancer Researchmedicine.medical_specialtyMaximum Tolerated DoseAntineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedGastroenterologyHypomagnesemiaCohort StudiesYoung AdultPharmacokineticsGrowth factor receptorNeoplasmsInternal medicineHumansMedicineDosingEpidermal growth factor receptorAdverse effectAgedGlycoproteinsAged 80 and overDose-Response Relationship Drugbiologybusiness.industryMiddle Agedmedicine.diseaseRashErbB ReceptorsOncologyPharmacodynamicsbiology.proteinFemalemedicine.symptombusinessJournal of Clinical Oncology
researchProduct

Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicente…

2006

This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as third- or fourth-line therapy in a retrospective series of patients with metastatic colorectal cancer refractory to oxaliplatin and irinotecan. Patients and Methods: Most patients (90%) had been previously treated with adjuvant 5-fluorouracil/leucovorin, and all had received oxaliplatin-based regimens before receiving irinotecan- based second-line treatment. Sixty patients with irinotecan-refractory colorectal cancer received a regimen comprising weekly irinotecan 120 mg/m 2 as a 1-hour intravenous infusion and cetuximab 400 mg/m 2 infused over 2 hours as the initial dose and 250 mg/m 2 infus…

AdultMaleOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSettore MED/06 - Oncologia MedicaColorectal cancermedicine.medical_treatmentCetuximabAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisSurvival analysisAgedAged 80 and overChemotherapyCetuximabPerformance statusbusiness.industryGastroenterologyAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesOxaliplatinErbB ReceptorsIrinotecanSettore MED/18 - Chirurgia GeneraleRegimenOncologyCamptothecinFemaleEpidermal growth factor receptor Oxaliplatin Vascular endothelial growth factorColorectal Neoplasmsbusinessmedicine.drugClinical Colorectal Cancer
researchProduct

Immunohistochemical expression of EGFR in oral leukoplakia: Association with clinicopathological features and cellular proliferation

2012

Objectives: to investigate the immunoexpression of epidermal growth factor receptor (EGFR) in a sample of oral leukoplakias (OL) and to determine the receptor’s association with dysplasia, tobacco consumption, lesion site, and proliferation rate. Although EGFR should be overexpressed in some oral leukoplakias, the factors that may interfere with this expression and the influence of this receptor on epithelial proliferation have yet to be investigated. Study Design: Samples of oral leukoplakias (48) and of normal oral epithelium (10) were immunohistologically examined for expression of EGFR. Immunohistochemistry for Ki-67, and p27 were also performed in leukoplakias. EGFR expression was asso…

AdultMalePathologymedicine.medical_specialtyEpithelial dysplasiaYoung Adultstomatognathic systemOral and maxillofacial pathologymedicineHumansEpidermal growth factor receptorGeneral DentistryPathologicalAgedCell ProliferationLeukoplakiaOral Medicine and Pathologybiologybusiness.industryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseImmunohistochemistryErbB Receptorsstomatognathic diseasesOtorhinolaryngologyDysplasiaKi-67UNESCO::CIENCIAS MÉDICASbiology.proteinImmunohistochemistryResearch-ArticleFemaleSurgeryLeukoplakia OralbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Brain abscess formation within an endodermal cyst of the frontal lobe: case report.

2009

A 38-year-old man with a right frontal lobe cyst was treated by endoscopic cystoventriculostomy in 1998. Cyst capsule histology revealed surprisingly an endodermal cyst. The patient was reoperated for cyst expansion by endoscopic re-cystoventriculostomy in 2005. In 2007, the patient suffered from brain abscess formation within the cyst which was punctured. The history was positive for a dental infection. In 2008, a recurrent brain abscess in the cyst occurred. The cyst was completely resected. There was no history of trauma or sinusitis. In all, endodermal cysts may mimic a paraxial arachnoid cyst. It may predispose for recurrent brain abscess formation - especially due to bacteraemia. This…

AdultMalePathologymedicine.medical_specialtyMicrosurgeryEpidermal CystBrain AbscessNeurosurgical ProceduresColloid CystsDiagnosis DifferentialArachnoid cystRecurrenceparasitic diseasesEnterobacter cloacaemedicineHumansCystSinusitisCentral Nervous System CystsBrain abscessbusiness.industryEnterobacteriaceae InfectionsHistologyGeneral MedicineAnatomymedicine.diseaseMagnetic Resonance ImagingFrontal LobeRight frontal lobeArachnoid CystsFrontal lobeEndodermal cystSurgeryNeurology (clinical)businessTomography X-Ray ComputedMinimally invasive neurosurgery : MIN
researchProduct

Epidermal growth factor receptor expression in different subtypes of oral lichenoid disease

2013

The oral lichenoid disease (OLD) includes different chronic inflammatory processes such as oral lichen planus (OLP) and oral lichenoid lesions (OLL), both entities with controversial diagnosis and malignant potential. Epidermal growth factor receptor (EFGR) is an important oral carcinogenesis biomarker and overexpressed in several oral potentially malignant disorders. Objectives: To analyze the EGFR expression in the OLD to find differences between OLP and OLL, and to correlate it with the main clinical and pathological features. Material and Methods: Forty-four OLD cases were studied and classified according to their clinical (Group C1: only papular lesions / Group C2: papular and other le…

AdultMalePathologymedicine.medical_specialtyOdontologíaDiseasemedicine.disease_causeLesionmedicineHumansEpidermal growth factor receptorGeneral DentistryPathologicalAgedAged 80 and overOral Medicine and Pathologybiologybusiness.industryResearchMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludErbB Receptorsstomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASbiology.proteinBiomarker (medicine)ImmunohistochemistrySurgeryOral lichen planusFemalemedicine.symptomCarcinogenesisbusinessLichen Planus Oral
researchProduct

Otoneurological management of petrous apex cholesterol granuloma

2009

Objective: The aim of the study is to review the management of petrous apex cholesterol granuloma. The surgical approaches for drainage or total removal and the wait and see policy were analyzed, and outcomes were evaluated. Methods: Retrospective charts of 27 patients managed for petrous apex cholesterol granuloma with a minimum follow-up of 12 months were analyzed in a quartenary skull base center. Presenting symptoms and signs were recorded, and radiologic imaging was evaluated. Management options included wait and see policy and surgery by several approaches. Results: The mean age of patients affected by the lesion was 38.8 years. The mean follow-up was 56.7 months. Patients complained …

AdultMalemedicine.medical_specialtyAdolescentEpidermal CystDiagnosis DifferentialYoung AdultTrigeminal neuralgiaVertigomedicine.arterymedicineHumansChildpetrous apexRetrospective StudiesDiplopiabiologyPetrous Apexbusiness.industryGranuloma Foreign-Bodycholesterol granulomaInfratemporal fossaskull baseMiddle Agedmedicine.diseasebiology.organism_classificationMagnetic Resonance ImagingSurgeryArachnoid Cystsmedicine.anatomical_structureCholesterolTreatment OutcomeOtorhinolaryngologyDrainageFemaletemporal bonemedicine.symptomInternal carotid arteryBone DiseasesbusinessTomography X-Ray ComputedTinnitusHemifacial spasmFollow-Up StudiesPetrous Bone
researchProduct

VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab

2008

AIM: To gain mechanistic insights into the role played by epidermal growth factor receptor (EGFR) in the regulation of vascular endothelial growth factors (VEGFs) in colorectal cancer (CRC). METHODS: The impact of high-level expression of the growth factor receptors EGFR and VEGF receptor (VEGFR)3 and the VEGFR3 ligands VEGF-C and VEGF-D on disease progression and prognosis in human CRC was investigated in 108 patients using immunohistochemistry. Furthermore, the expression of the lymphangiogenic factors in response to the modulation of EGFR signalling by the EGFR-targeted monoclonal antibody cetuximab was investigated at the mRNA and protein level in human SW480 and SW620 CRC cell lines an…

AdultPathologymedicine.medical_specialtyColorectal cancerTransplantation HeterologousVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DCetuximabAntineoplastic AgentsMice SCIDAntibodies Monoclonal HumanizedMiceGrowth factor receptorMice Inbred NODCell Line TumorMedicineAnimalsHumansEpidermal growth factor receptorneoplasmsAgedColorectal CancerAged 80 and overCetuximabbiologyintegumentary systembusiness.industryGastroenterologyVascular Endothelial Growth Factor DAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseVascular Endothelial Growth Factor Receptor-3digestive system diseasesLymphangiogenesisErbB ReceptorsVascular endothelial growth factor CCancer researchbiology.proteinImmunohistochemistryFemalebusinessColorectal NeoplasmsNeoplasm Transplantationmedicine.drugSignal Transduction
researchProduct

Dermoid and epidermoid cysts of the oral cavity : a 48-year retrospective study with focus on clinical and morphological features and review of main …

2020

Background Dermoid and epidermoid cysts are slow-growing, benign developmental cysts that arise from ectodermal tissue and can occur anywhere in the body. Less than 7% of these cysts involve the head and neck region, with only 1.6% of cases presenting in the oral cavity. To evaluate the clinical and histopathological features of dermoid (DCs) and epidermoid (ECs) cysts stored in the archives of a referred Oral Pathology Service over a 48-year-period, and to review current concepts about these cysts. Material and Methods All DCs and ECs were reviewed, and clinical data were obtained from the patient records. Fourteen cases of DCs and thirteen cases of ECs were re-evaluated microscopically by…

AdultPathologymedicine.medical_specialtyEpidermal CystEpidermal CystAdipose tissueStratified squamous epitheliumEpithelium03 medical and health sciences0302 clinical medicineOral and maxillofacial pathologymedicineHumansGeneral DentistryDermoid CystRetrospective StudiesMouthOral Medicine and Pathologybusiness.industryResearch030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Epitheliummedicine.anatomical_structureOtorhinolaryngologyDermoid cystGiant cellUNESCO::CIENCIAS MÉDICASRespiratory epitheliumFemaleSurgerybusiness
researchProduct

Congenital hypertrophy of the retinal pigment epithelium and familial polyposis of the colon.

1987

Inquiries to Manuel Diaz Llopis, M.D., Cl Cirilo Amoros No. 1 PTA 2, Valencia 46004, Spain. Familial polyposis of the colon is a dominant autosomal disorder that is characterized by hundreds and sometimes thousands of adenomatous polyps throughout the entire colon, which begin in adolescence. Virtually all pa­ tients with familial polyposis develop carcino­ ma of the colon by age 50 years. A total colectomy should be carried out early in adult life in affected persons. Because of the autosomal dominant inheritance pattern, an intensive sur­ vey of family members must be conducted. There is no phenotype biochemical abnormality or serologic marker that indicates whether a familial member will…

AdultPathologymedicine.medical_specialtyMicrocephalyRetinal pigment epitheliumEpidermal Cystbusiness.industryDiseaseHypertrophymedicine.diseaseMuscle hypertrophySerologyOphthalmologyCongenital hypertrophymedicine.anatomical_structureAdenomatous Polyposis ColiRetinal DiseasesmedicineHumansAbnormalityFluorescein AngiographybusinessPigment Epithelium of EyeAmerican journal of ophthalmology
researchProduct